GlassScriptPhysician profile
Muriel Levy Kern
NPI 1629077797
$384.86
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $24.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $148.82 | 2019-2020 | |
| Corcept Therapeutics | $53.80 | 2019 | |
| Ibsa Pharma INC. | $53.35 | 2019-2020 | |
| Novo Nordisk INC | $39.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.50 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Abbvie INC. | $13.73 | 2019 | |
| Abbott Laboratories | $11.13 | 2019 | |
| Merck Sharp & Dohme LLC | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muriel Levy Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.